Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Abbott Laboratories's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $183.8B | |
|---|---|---|
| Revenue (ttm) | 48.2B | |
| Net income (ttm) | 4.7B | |
| EPS (ttm) | $2.69 | |
| Shares out | 1.7B | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 17.9x | |
| Dividend | $2.52 (2.45%) | |
| Volume | 4,052,721 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | +0.7% |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.33B | $24.61B | +1.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -1.4% |
| EBITDA | $12.16B | $11.89B | $10.61B | $10.83B | $11.55B | -1.3% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Recent company headlines from major financial publishers.
The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.
Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.3% | $99.9 | $106 | $115 | $127 | $146 |
| 6.3% | $87.9 | $91.7 | $96.6 | $103 | $111 |
| 7.3% | $79.6 | $82.1 | $86.7 | $88.8 | $93.4 |
| 8.3% | $73.4 | $75.2 | $77.2 | $79.6 | $82.5 |
| 9.3% | $68.7 | $69.9 | $71.4 | $73.0 | $74.9 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
